Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

Clegg, Lindsay E.; Penland, Robert C.; Bachina, Srinivas; Boulton, David W.; Thuresson, Marcus; Heerspink, Hiddo J. L.; Gustavson, Stephanie; Sjöström, C. David; Ruggles, James A.; Hernandez, Adrian F.; Buse, John B.; Mentz, Robert J.; Holman, Rury R.

doi:10.1186/s12933-019-0942-x

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanisms. However, evidence on clinical outcomes in patients treated with both GLP-1…